Premium
Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drug
Author(s) -
Kneller,
Raanani,
Hardan,
Avigdor,
; Levi,
Berkowicz,
BenBassat
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.01835.x
Subject(s) - thalidomide , refractory (planetary science) , medicine , multiple myeloma , chemotherapy , drug , gastroenterology , salvage therapy , oncology , surgery , pharmacology , biology , astrobiology
We have treated 17 refractory or relapsed multiple myeloma patients resistant to chemotherapy with thalidomide at a dose of 200–800 mg/day. Eleven patients responded, five of whom had a very good partial response (> 75% decline in M protein) and another five exhibited a partial response (> 50% decline in M protein). Except for one patient, treatment was well tolerated with only mild side‐effects. Thalidomide should be included in the therapeutic options for refractory myeloma.